Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Legendary Trader Peter Brandt Names Bullish XRP Target

Legendary Trader Peter Brandt Names Bullish XRP Target

UTodayUToday2026/10/06 11:51

The trader believes there is an emerging technical formation that could lead to the aforementioned bullish price target for the cryptocurrency.

A promising pattern 

The seasoned chartist stated he is seeing a cup-and-handle technical formation on the XRP chart. 

On a larger timeframe, it could also be the right shoulder of an inverse head-and-shoulders pattern.

Brandt says XRP price could hit $2.16 if the emerging technical pattern he's tracking ends up playing out. 

He set a potential $2.16 price target based on taking the height of this inverse head-and-shoulders formation on a daily closing price chart and extending it upwards.

Given that XRP is currently trading near $1.50, it would mean the token would need to rally around 44% for it to hit Brandt's potential price target.

However, technical patterns often don't hit their initial targets or sometimes transform into something entirely different.

The veteran trader explained he is a believer in the idea of "measured moves." 

Brandt also noted that this potential right shoulder of the technical pattern is "poorly formed" and "abbreviated." This could indicate that more of the right shoulder is still forming, but not necessarily.

Major XRP obstacle

Looking at a weekly chart, Brandt pointed out that XRP price is well off the major peaks from the previous rally. There could be a lot of holders at higher price levels that could sell as XRP goes higher, forming resistance.

"There is a TON of overhead supply to go through," said Brandt. He called it a negative for XRP.

The trader compared XRP to a number of other major cryptocurrencies. He claimed that Monero (XMR) has already worked through a lot of its overhead supply. He also said Solana shows a much better-looking cup-and-handle technical formation.

At the time of writing, XRP is trading around $1.50 and has a market cap of around $94.65 billion, per the provided CoinGecko data. Over the past month, XRP is up around 5.5%.  

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53